IC
BBIO icon

Innealta Capital’s BridgeBio Pharma BBIO Stock Holding History

Innealta Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-68
Closed -$1.72K – 313
2024
Q2 		$1.72K Buy
+68
New +$1.86K ﹤0.01% 1141

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Innealta Capital's BBIO Position: Q3 2024 in Review

Innealta Capital sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 68 shares — an estimated $1.72K sold.

Innealta Capital first reported a position in BBIO in Q2 2024 and held it in 1 quarter. The position peaked at $1.72K in Q2 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • Innealta Capital reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 68 BridgeBio Pharma shares in Q3 2024, an estimated $1.72K.
  • Innealta Capital first reported a position in BridgeBio Pharma in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's BridgeBio Pharma position peaked at $1.72K in Q2 2024.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.